Search Results - "MOLLON, Delphine"

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients by Berton, Dominique, Floquet, Anne, Lescaut, Willy, Baron, Gabriel, Kaminsky, Marie-Christine, Toussaint, Philippe, Largillier, Rémy, Savoye, Aude-Marie, Alexandre, Jérôme, Delbaldo, Catherine, Malaurie, Emmanuelle, Barletta, Hugues, Bosacki, Claire, Garnier-Tixidre, Claire, Follana, Philippe, Laharie-Mineur, Hortense, Briac Levache, Charles, Valenza, Bruno, Dechartres, Agnès, Mollon-Grange, Delphine, Selle, Frédéric

“…Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized…”
Get full text

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial by Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Dalenc, Florence, Bachelot, Thomas, Pierga, Jean-Yves, de la Motte Rouge, Thibault, Sabatier, Renaud, Dubot, Coraline, Ferrero, Jean Marc, Ladoire, Sylvain, Levy, Christelle, Mouret-Reynier, Marie-Ange, Lortholary, Alain, Grenier, Julien, Chakiba, Camille, Stefani, Laetitia, Plaza, Jérôme Edouard, Clatot, Florian, Teixeira, Luis, D'Hondt, Véronique, Vegas, Hélène, Derbel, Olfa, Garnier-Tixidre, Claire, Canon, Jean-Luc, Pistilli, Barbara, André, Fabrice, Bièche, Ivan, Callens, Céline, Lemonnier, Jérôme, Delaloge, Suzette, PISTILLI, Barbara, DALENC, Florence, BACHELOT, Thomas, SABATIER, Renaud, DUBOT, Coraline, FRENEL, Jean-Sébastien, FERRERO, Jean-Marc, LADOIRE, Sylvain, LEVY, Christelle, MOURET-REYNIER, Marie-Ange, HARDY-BESSARD, Anne-Claire, LORTHOLARY, Alain, GRENIER, Julien, CHAKIBA, Camille, STEFANI, Laetitia, SOULIE, Patrick, PLAZA, Jérôme Edouard, CLATOT, Florian, TEIXEIRA, Luis, D'HONDT, Véronique, VEGAS, Hélène, DERBEL, Olfa, GARNIER TIXIDRE, Claire, CHENEAU, Caroline, PAITEL, Jean-François, BERNARD-MARTY, Chantal, SPAETH, Dominique, MOULLET, Isabelle, DEIANA, Laura, GREILSAMER, Charlotte, VENAT-BOUVET, Laurence, DELECROIX, Valérie, MELIS, Adrien, ORFEUVRE, Hubert, NGUYEN, Suzanne, LEGOUFFE, Eric, ZANNETTI, Alain, LE SCODAN, Romuald, DOHOLLOU, Nadine, DALIVOUST, Philippe, ARSENE, Olivier, MARQUES, Nathalie, PETIT, Thierry, MOLLON, Delphine, DAUBA, Jérôme, BONNIN, Nathalie, GARDNER, Miriam, MARTI, Adina, LEVACHE, Charles-Briac, LACHAIER, Emma, ACHILLE, Mihaela, VALMAR, Christophe, BOUAITA, Ryan, MEDIONI, Jacques, FOA, Cyril, DEL PIANO, Francesco, GOZY, Michel, ESCANDE, Anne, LEDUC, Nicolas, LUCAS, Brigitte, AMMARGUELLAT, Hanifa, NAJEM, Abeer, TROUBOUL, Fanny, DESCLOS, Hervé, MAYEUR, Didier, LORCHEL, Fabrice, BOUDRANT, Axelle, GISSEROT, Olivier, ALLEAUME, Corinne, DE GRAMONT, Aimery

“…In advanced oestrogen receptor-positive, HER2-negative breast cancer, acquired resistance to aromatase inhibitors frequently stems from ESR1-mutated subclones,…”
Get full text

Abstract PS12-05: First efficacy results of a 2-stage Simon’s design randomised phase 2 of darolutamide or capecitabine in patients with triple-negative, androgen receptor positive advanced breast cancer (UCBG06-3) by Bonnefoi, Hervé, Lerebours, Florence, Tredan, Olivier, Dalenc, Florence, Levy, Christelle, Saghatchian, Mahasti, Reynier, Marie Ange Mouret, Mollon, Delphine, Guiu, Severine, Bouvet, Laurence Venat, Carola, Elisabeth, Martineau, Geraldine, Pulido, Marina, MacGrogan, Gaetan, Goncalves, Anthony

“…Abstract Background: Triple negative breast cancer (TNBC) is an heterogeneous disease and encompasses at least 4 subtypes. One of these expresses the androgen…”
Get full text

Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients by Voog, Eric, Campillo‐Gimenez, Boris, Elkouri, Claude, Priou, Franck, Rolland, Frederic, Laguerre, Brigitte, Elhannani, Chaza, Merrer, Jacques, Pfister, Christian, Sevin, Emmanuel, L'Haridon, Tifenn, Hasbini, Ali, Moise, Laura, Le Rol, Annick, Malhaire, Jean Pierre, Delva, Remy, Vauléon, Elodie, Cojocarasu, Oana, Deguiral, Philippe, Cumin, Isabelle, Cheneau, Caroline, Schlürmann, Friedrike, Delecroix, Valérie, Boughalem, Elouen, Mollon, Delphine, Ligeza‐Poisson, Catherine, Abadie‐Lacourtoisie, Sophie, Monpetit, Erik, Chatellier, Thierry, Desclos, Henry, Coquan, Elodie, Joly, Florence, Tessereau, Jean Yves, Dupuy, Sandra, Déniel Lagadec, Delphine, Marhuenda, Fanny, Grudé, Francoise

“…The treatment landscape in metastatic renal cell carcinoma has changed fundamentally over the last decade by the development of antiangiogenic agents,…”
Get full text

Non-pegylated liposomal doxorubicin (NPLD, Myocet®) + carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial by Romeo, Clémence, Joly, Florence, Ray-Coquard, Isabelle, El Kouri, Claude, Mercier-Blas, Anne, Berton-Rigaud, Dominique, Kalbacher, Elsa, Cojocarasu, Oana, Fabbro, Michel, Cretin, Jacques, Zannetti, Alain, Abadie-Lacourtoisie, Sophie, Mollon, Delphine, Hardy-Bessard, Anne-Claire, Provansal, Magali, Blot, Emmanuel, Delbaldo, Catherine, Lesoin, Anne, Freyer, Gilles, You, Benoît

“…Carboplatin and pegylated liposomal doxorubicin combination is a standard regimen in platinum-sensitive recurrent ovarian cancer patients. The pegylated…”
Get full text

Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma by Abgral, Ronan, Le Roux, Pierre-Yves, Keromnes, Nathalie, Rousset, Jean, Valette, Gérald, Gouders, Dominique, Leleu, Cyril, Mollon, Delphine, Nowak, Emmanuel, Querellou, Solène, Salaün, Pierre-Yves

“…Purpose Locally advanced head and neck squamous cell carcinoma (HNSCC) has a high rate of recurrence. Induction chemotherapy with DCF (docetaxel, cisplatin,…”
Get full text

Abstract PD9-08: Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of everolimus (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC) by Penault-Llorca, Frederique, Dalenc, Florence, Chabaud, Sylvie, Cottu, Paul, Allouache, Djelila, Cameron, David, Jacquin, Jean-Philippe, Grenier, Julien, Bouvet, Laurence Venat, Jegannathen, Apurna, Campone, Mario, Piano, Francesco Del, Debled, Marc, Hardy-Bessard, Anne-Claire, Giacchetti, Sylvie, Barthelemy, Philippe, Kaluzinski, Laure, Mailliez, Audrey, Mouret-Reynier, Marie-Ange, Legouffe, Eric, Cayre, Anne, Martinez, Mathilde, Delbaldo, Catherine, Mollon-Grange, Delphine, Macaskill, E. Jane, Sephton, Matthew, Stefani, Laëtitia, Belgadi, Blaha, Winter, Matthew, Orfeuvre, Hubert, Lacroix-Triki, Magali, Bonnefoi, Herve, Bliss, Judith, Canon, Jean-Luc, Lemonnier, Jerome, Andre, Fabrice, Bachelot, Thomas

“…Abstract Background: The double blind randomized UNIRAD trial (NCT01805271) showed no evidence that adding Everolimus (EVE) to adjuvant endocrine therapy (EHT)…”
Get full text

Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study by Falandry, Claire, Pommeret, Fanny, Gladieff, Laurence, Tinquaut, Fabien, Lorusso, Domenica, Mouret-Reynier, Marie-Ange, D'Hondt, Véronique, Mollon-Grange, Delphine, Floquet, Anne, Abadie-Lacourtoisie, Sophie, Brachet, Pierre-Emmanuel, Stefani, Laetitia, Rousseau, Frédérique, Frenel, Jean-Sébastien, Del Piano, Francesco, Komulainen, Marja, Warkus, Thomas, Trédan, Olivier, Pujade-Lauraine, Eric, Freyer, Gilles

“…Older patients with ovarian cancer represent a heterogeneous population. The French National Group of Investigators for the Study of Ovarian and Breast Cancer…”
Get full text